In Section A, contributors will obtain various doses and schedules of oral ABBV-744 tablet to detect Risk-free dosing program. Additional individuals are going to be enrolled on the discovered monotherapy dosign program. In Segment B, participants will obtain oral ruxolitinib and ABBV-744 are going to be offered as "incorporate-on" therapy. https://geneb322oyi4.onzeblog.com/profile